PLANO, Texas, March 09, 2023 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that Joe Dziedzic, President and Chief Executive Officer, and Jason Garland, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum at 10:30am ET on Tuesday, March 21, 2023.
Interested parties may access a live and archived webcast of the fireside chat on the company’s investor relations website at: investor.integer.net.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military, and environmental markets. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.
Investor Relations: | Media Relations: | |
Andrew Senn | Kelly Butler | |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. | |
763.951.8312 | 214.618.4216 |
Last Trade: | US$143.28 |
Daily Change: | 1.84 1.30 |
Daily Volume: | 229,024 |
Market Cap: | US$4.810B |
October 24, 2024 September 23, 2024 August 22, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load